Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BN104 in Combination Therapy for AML with KMT2A/NPM1/NUP98 Alterations
ChiCTR2400093165Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of vicrimenib in acute myeloid leukemia (AML) (6 arms), sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: Incidence of dose-limiting toxicities (DLT), Incidence of serious adverse events (SAE) and 1 more. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
vicrimenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2400093165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093165.